Free tool
FAERS Monitor: Vaseretic
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019221 or its brand name (Vaseretic, Enalapril Maleate, Hydrochlorothiazide). Reports on generic versions are filed under their own applications.
Reports
912
Serious
787
86% of reports
Hospitalization
507
Death reported
61
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug interaction58
- diarrhoea54
- nausea48
- fall45
- renal failure acute44
- dizziness38
- vomiting36
- hypotension35
- hyponatraemia34
- renal failure34
- dyspnoea32
- drug ineffective31
- fatigue30
- headache29
- hypertension29
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 73 |
| 2005 | 79 |
| 2006 | 67 |
| 2007 | 42 |
| 2008 | 73 |
| 2009 | 72 |
| 2010 | 85 |
| 2011 | 120 |
| 2012 | 90 |
| 2013 | 11 |
| 2014 | 22 |
| 2015 | 17 |
| 2016 | 19 |
| 2017 | 13 |
| 2018 | 36 |
| 2019 | 24 |
| 2020 | 31 |
| 2021 | 13 |
| 2022 | 5 |
| 2023 | 9 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,247 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| renal failure acuteSignal | 44 | 23.9 | 17.9 | 946 |
| hyponatraemiaSignal | 34 | 13.9 | 10.0 | 396 |
| drug interactionSignal | 58 | 8.4 | 6.6 | 375 |
| renal failureSignal | 34 | 5.9 | 4.2 | 135 |
| hypotensionSignal | 35 | 4.0 | 2.9 | 77 |
| hypertensionSignal | 29 | 3.2 | 2.2 | 41 |
| fallSignal | 45 | 3.1 | 2.3 | 64 |
| diarrhoea | 54 | 1.9 | 1.5 | 24 |
| vomiting | 36 | 1.8 | 1.3 | 11 |
| dizziness | 38 | 1.8 | 1.3 | 12 |
| nausea | 48 | 1.4 | 1.1 | 5 |
| dyspnoea | 32 | 1.3 | 0.9 | 2 |
| headache | 29 | 1.1 | 0.7 | 0 |
| fatigue | 30 | 0.9 | 0.6 | 0 |
| drug ineffective | 31 | 0.5 | 0.4 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.